Product Description | GILGFVFTL is a 9-amino acid peptide derived from the Influenza A matrix protein 1 (M1), specifically from residues 58-66. This epitope is recognized by CD8+ cytotoxic T lymphocytes (CTLs) and is presented by the human major histocompatibility complex (MHC) class I molecule HLA-A*02:01. Due to its immunodominant nature, GILGFVFTL is extensively utilized in immunological research, particularly in assays assessing T-cell responses to influenza infection. GILGFVFTL is a valuable tool in immunological research, offering robust applications such as: CD8+ T-Cell Stimulation: Used in T-cell assays, including ELISPOT, intracellular cytokine staining (ICS), cytotoxicity, and proliferation assays. Antigen Loading: Compatible with dextramers/tetramers for antibody production. Research and Development: Assists in mapping T-cell epitopes, immune monitoring, and vaccine development. |
Scientific Background | GILGFVFTL is a 9-residue synthetic peptide with the sequence Gly-Ile-Leu-Gly-Phe-Val-Phe-Thr-Leu. The sequence has a relatively high hydrophobic-residue fraction that can influence aqueous solubility and surface adsorption. These sequence-derived properties describe the reagent chemically; no specific receptor, enzyme, pathway, disease association, or biological activity is assigned without product-specific experimental evidence. |
Experimental Notes | Sequence-derived chemical properties support reagent selection and experimental planning but do not establish biological function. Solubility, aggregation, adsorption, conjugation efficiency, and assay performance should be validated under the intended experimental conditions. |
